7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`a
`
`iHealthcareAnalyst
`
`Updated Data Matrix Available
`Market Value | Market Volume | Epidemiology | Clinical Trials | Patent
`Landscape | Regulatory Approvals
`
`Home » Publications » Press Releases
`
`Global CINV Drugs Market $4.3 Billion by 2031
`February 3, 2025 by iHealthcareAnalyst, Inc.
`
`The global market for chemotherapy-induced nausea and vomiting
`(CINV) drugs estimated to reach $4.3 billion by 2031, expanding at a
`CAGR of 8.2% over the forecast period, driven by recent advances in
`medications, and increase in the number of highly effective agents to
`treat chemotherapy-induced nausea and vomiting condition.
`
`e Other market driving factors include increasing number of
`patients undergoing chemotherapy treatments and newly
`
`annroved driias with minimiim <ide-effects Rilkacysdems
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 1/12
`
`HELSINN EXHIBIT 2006
`
`Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.
`
`Page 1 of 12 IPR2025-00947
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`Limited-Time Offer [Flat 15% Discount] Dismiss
`
`e e
`
`Chemotherapy-induced nausea and vomiting (CINV) classified as
`acute, delayed or anticipatory based on the timing and type of
`chemotherapy drugs involved. Incidence and timing of CINV vary
`according to patient factors and chemotherapeutic agents. Incidence
`has been reported in as high as 70%-80% of patients.
`
`The most commonly referred to published guidelines from the
`American Society of Clinical Oncology (ASCO), the Oncology Nursing
`Society (ONS) and the National Comprehensive Cancer Network
`(NCCN) clearly delineate the prevention and treatment of CINV.
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 2/12
`
`Page 2 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM
`
`The global chemotherapy-induced nausea and vomiting (CINV) drugs
`
`Global CINV Drugs Market $4.3 Billion by 2031
`
`prophylactic antiemetics for chemotherapy regimens with
`emetogenic potential less than 10%.
`e The three categories of drugs with the highest therapeutic
`
`index for the management of CINV include:
`
`Type three 5-hydroxytryptamine (5-HT3) receptor
`
`antagonists,
`
`Neurokinin-1 receptor (NK1R) antagonists,
`
`Glucocorticoids (especially dexamethasone).
`
`5-HT3 serotonin receptor antagonists include dolasetron,
`
`granisetron, ondansetron and palonosetron.
`
`Neurokinin 1 (NK1) receptor antagonists are used for
`
`delayed CINV include aprepitant (oral formulation) and
`
`fosaprepitant (IV formulation).
`
`Corticosteroids include dexamethasone and
`
`methylprednisone, whereas other miscellaneous agents
`
`include metoclopramide, compazine, cannabinoids,
`
`benzodiazepines, and antihistamines.
`
`e These agents are used alone and in specific
`combinations, depending on the emetogenicity of the
`
`specific chemotherapy regimen being administered and
`its tendency to produce not only acute but also delayed
`
`emesis.
`
`market report provides market size ($million 2021 to 2031), market
`share, growth trends and forecast (CAGR%, 2025 to 2031).
`
`The global market for chemotherapy-induced nausea and vomiting
`treatment seamented bv product [marketed druas [5-HT3-receptor
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/
`
`Page 3 of 12
`
`3/12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`generic (ondansetron), Kytril generic (granisetron), neurokinin-
`receptor antagonists — Emend (aprepitant) / Proemend (fosaprepitant
`meglumine) / Cinvanti (aprepitant), netupitant-palonosetron fixed-
`dose combination IV (NEPA FDC) — Akynzeo (Netupitant-palonosetron
`FDCQ)], pipeline drugs [5-HT3-receptor antagonists — SUSTOL
`(Granisetron injection — extended release), neurokinin1-receptor
`antagonists — Varubi / Varuby (rolapitant)], and geography.
`
`e Nausea and vomiting are serious side effects of cancer
`chemotherapy that can cause significant negative impacts on
`patients’ quality of life and on their ability to tolerate and
`comply with therapy.
`
`e Despite advances in the prevention and management of
`chemotherapy-induced nausea and vomiting (CINV), these
`side effects remain among the most distressing for patients.
`
`e The use of emerging antiemetic medications has
`reduced the incidence of vomiting substantially, but
`evaluations show that approximately 30% to 60% of
`patients still experience either acute or delayed nausea
`after chemotherapy.
`
`e Based on the marketed products category, the Aloxi
`(palonosetron) drug segment accounted for the largest share
`of the total CINV market.
`
`e Currently, four 5-HT3 receptor antagonists are available in
`the United States -ondansetron, granisetron, dolasetron,
`and palonosetron.
`
`e Since their introduction, 5-HT3 receptor antagonists
`have become part of the cornerstone for CINV
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 4/12
`
`Page 4 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`effect profile.
`
`e Aloxi is one of the most commonly prescribed drugs to
`treat CINV. Palonosetron, the newest agent, was approved
`in 2003.
`
`e |tisis available in oral as well as IV dosage forms,
`indicated in adults for the prevention of acute and
`delayed nausea and vomiting associated with moderate
`to high emetogenic chemotherapy.
`
`e Evidence suggests that the 5-HT3-receptor
`antagonists administered in combination with
`corticosteroids afford the best protection from
`symptoms of acute emesis and, by extrapolation, the
`most effective prevention of delayed emesis.
`
`The global CINV treatment market research report is further divided
`by geography North America (U.S., Canada), Europe (U.K., Germany,
`France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest
`of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the
`World.
`
`e Geographically, the North America region represented the
`largest market share of the total CINV drugs in terms of
`revenue, followed by the Europe region, primarily due to the
`increasing incidence of various types of cancer and anticipated
`product approval during the next few years.
`
`e On the other hand, the emerging markets in the Asia Pacific
`region expected to exhibit huge opportunities characterized
`by increasing market penetration by generic manufacturers,
`durina the forecast period.
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 5/12
`
`Page 5 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`(market drivers, restraints, opportunities), market attractiveness
`analysis and profiles of major competitors in the global market
`including company overview, financial snapshot, key products,
`technologies and services offered, and recent developments.
`
`Major competitors operating in the global market for chemotherapy-
`induced nausea and vomiting treatment and included in this report
`are GSK plc (Tesaro, Inc. / GlaxoSmithKline), Helsinn Holding S.A.,
`Heron Therapeutics, Inc., Merck & Co., Inc., and Ono Pharmaceutical
`Co., Ltd.
`
`e Product
`e Marketed Drugs
`e 5-HT3-receptor Antagonists (5-HT3RAs)
`e Aloxi (palonosetron)
`* Anzemet (dolasetron)
`e Zofran Generic (ondansetron)
`e Kytril Generic (granisetron)
`e Neurokinin1-receptor Antagonists (NK1RAs)
`e Emend (aprepitant) / Proemend (fosaprepitant
`meglumine) / Cinvanti (aprepitant)
`e Netupitant-Palonosetron Fixed-Dose Combination IV
`(NEPA FDCQ)
`e Akynzeo (netupitant/palonosetron FDC)
`e Pipeline Drugs
`e 5-HT3-receptor Antagonists (5-HT3RAs)
`e SUSTOL (Granisetron Injection — extended release)
`e Neurokinin1-receptor Antagonists (NK1RAs)
`e Varubi / Varubv (rolanitant)
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 6/12
`
`Page 6 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`Limited-Time Offer [Flat 15% Discount] Dismiss
`e North America (U.S., Canada)
`
`e Europe (U.K, Germany, France, Italy, Spain, Rest of EU)
`e Asia Pacific (Japan, China, India, Rest of APAC)
`e Latin America (Brazil, Mexico, Rest of LA)
`e Rest of the World
`e Company Profiles
`e GSK plc (Tesaro, Inc. / GlaxoSmithKline)
`e Helsinn Holding S.A. (Helsinn Healthcare/ Helsinn Group)
`e Heron Therapeutics, Inc.
`e Merck & Co., Inc.
`e Ono Pharmaceutical Co., Ltd.
`
`To request Table of Contents and Sample Pages of this report visit:
`https:.//www.ihealthcareanalyst.com/report/chemotherapy-induced-
`nausea-and-vomiting-drugs-market/
`
`Related publications:
`
`e Chemotherapy-Induced Nausea and Vomiting Drugs Market by
`Major Drugs (Marketed Drugs, and Pipeline Drugs) and
`Forecast 2024-2031
`
`e Post-operative Nausea and Vomiting (PONV) Market by
`Treatment (Pharmacological Treatment — Dopamine
`Antagonists, NK-1 Receptor Antagonists, Serotonin
`Antagonists, Steroids, and Non-pharmacological Treatment); by
`Distribution Channel (Hospital Pharmacies, Online Pharmacies,
`Retail Pharmacies & Drug Stores) and Forecast 2024-2031
`
`e Global mHealth Services Market $315 Billion by 2031
`
`e Global Anticoaaulant Druas Market $32.7 Billion bv 2029
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/
`
`Page 7 of 12
`
`7112
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`2029
`
`BB Press Releases
`< Global Video Telemedicine Market $3.4 Billion by 2031
`
`> Global Airway Clearance Devices Market $870 Million by 2031
`Request Table of Contents/Sample Analysis
`
`Full Name*
`
`Company Email*
`
`Phone Number* [Please add country code]
`
`Subject*
`
`Global Chemotherapy-inc
`
`Message*
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 8/12
`
`Page 8 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`Market Data Matrix
`
`Market Value | Market Volume | Epidemiology | Clinical Trials | Patent
`Landscape | Regulatory Approvals | COVID-19 Impact Analysis
`
`Recent Publications
`
`Global Ambulatory Surgical and Emergency Center Services Market $125
`Billion by 2031
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 9/12
`
`Page 9 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`Limited-Time Offer [Flat 15% Discount] Dismiss
`
`Global Emphysema Treatment Devices Market $2.9 Billion by 2031
`
`Global Chronic Low Back Pain Devices Market $17.5 Billion by 2031
`
`Global Metabolic Bone Diseases Devices Market $7.5 Billion by 2031
`
`Global Tumor Microwave Ablation Market $282 Million by 2031
`
`Global Epilepsy Treatment Devices Market $7.4 Billion by 2031
`
`Global Surgical Robots Market $135 Billion by 2031
`
`Global Uterine Fibroids Embolization Devices Market $3.5 Billion by 2031
`
`Global Contrast Media Formulations Market $11.2 Billion by 2031
`
`Global Multi-Cancer Early Detection Assays Market $3.5 Billion by 2031
`
`Global Minimal Residual Disease Diagnostics Market $5.1 Billion by 2031
`
`Global Atrial Fibrillation Therapy Devices Market $19.5 Billion by 2031
`
`Global Bone Cancer Regeneration and Repair Devices Market $3.5 Billion
`by 2031
`
`Revenue Forecasting Techniques for New Pharmaceutical Drugs
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 10/12
`
`Page 10 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`Receive latest published reports, industry trends and future market outlook.
`
`Full Name*
`
`Company Email*
`
`Phone Number* [Please add country code]
`
`Resource Links
`
`e About Us
`
`e Clinical Trials
`
`e Drugs@FDA
`
`e Orange Book
`
`e Premarket Approval
`
`e Premarket Notification
`e Publications
`
`Terms and Conditions
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 1112
`
`Page 11 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`e (Careers
`
`e Terms of Use
`
`e How to Order
`
`e Return Policy
`
`e Privacy Policy
`
`e Disclaimer Policy
`
`Secure Online Payment
`
`[ 2 eem——.] | |
`VISA mflg = PayPal
`
`Search
`
`Contact Address
`
`US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043,
`United States
`
`Phone: +1 (314) 315-4764
`
`India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager,
`Pune 411005, India
`
`Phone: +91 (20) 25898524
`
`Email: sales@ihealthcareanalyst.com
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 12/12
`
`Page 12 of 12
`
`
`
`
`
`
`
`
`
`
`a
`
`iHealthcareAnalyst
`
`Updated Data Matrix Available
`Market Value | Market Volume | Epidemiology | Clinical Trials | Patent
`Landscape | Regulatory Approvals
`
`Home » Publications » Press Releases
`
`Global CINV Drugs Market $4.3 Billion by 2031
`February 3, 2025 by iHealthcareAnalyst, Inc.
`
`The global market for chemotherapy-induced nausea and vomiting
`(CINV) drugs estimated to reach $4.3 billion by 2031, expanding at a
`CAGR of 8.2% over the forecast period, driven by recent advances in
`medications, and increase in the number of highly effective agents to
`treat chemotherapy-induced nausea and vomiting condition.
`
`e Other market driving factors include increasing number of
`patients undergoing chemotherapy treatments and newly
`
`annroved driias with minimiim <ide-effects Rilkacysdems
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 1/12
`
`HELSINN EXHIBIT 2006
`
`Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.
`
`Page 1 of 12 IPR2025-00947
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`Limited-Time Offer [Flat 15% Discount] Dismiss
`
`e e
`
`Chemotherapy-induced nausea and vomiting (CINV) classified as
`acute, delayed or anticipatory based on the timing and type of
`chemotherapy drugs involved. Incidence and timing of CINV vary
`according to patient factors and chemotherapeutic agents. Incidence
`has been reported in as high as 70%-80% of patients.
`
`The most commonly referred to published guidelines from the
`American Society of Clinical Oncology (ASCO), the Oncology Nursing
`Society (ONS) and the National Comprehensive Cancer Network
`(NCCN) clearly delineate the prevention and treatment of CINV.
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 2/12
`
`Page 2 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM
`
`The global chemotherapy-induced nausea and vomiting (CINV) drugs
`
`Global CINV Drugs Market $4.3 Billion by 2031
`
`prophylactic antiemetics for chemotherapy regimens with
`emetogenic potential less than 10%.
`e The three categories of drugs with the highest therapeutic
`
`index for the management of CINV include:
`
`Type three 5-hydroxytryptamine (5-HT3) receptor
`
`antagonists,
`
`Neurokinin-1 receptor (NK1R) antagonists,
`
`Glucocorticoids (especially dexamethasone).
`
`5-HT3 serotonin receptor antagonists include dolasetron,
`
`granisetron, ondansetron and palonosetron.
`
`Neurokinin 1 (NK1) receptor antagonists are used for
`
`delayed CINV include aprepitant (oral formulation) and
`
`fosaprepitant (IV formulation).
`
`Corticosteroids include dexamethasone and
`
`methylprednisone, whereas other miscellaneous agents
`
`include metoclopramide, compazine, cannabinoids,
`
`benzodiazepines, and antihistamines.
`
`e These agents are used alone and in specific
`combinations, depending on the emetogenicity of the
`
`specific chemotherapy regimen being administered and
`its tendency to produce not only acute but also delayed
`
`emesis.
`
`market report provides market size ($million 2021 to 2031), market
`share, growth trends and forecast (CAGR%, 2025 to 2031).
`
`The global market for chemotherapy-induced nausea and vomiting
`treatment seamented bv product [marketed druas [5-HT3-receptor
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/
`
`Page 3 of 12
`
`3/12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`generic (ondansetron), Kytril generic (granisetron), neurokinin-
`receptor antagonists — Emend (aprepitant) / Proemend (fosaprepitant
`meglumine) / Cinvanti (aprepitant), netupitant-palonosetron fixed-
`dose combination IV (NEPA FDC) — Akynzeo (Netupitant-palonosetron
`FDCQ)], pipeline drugs [5-HT3-receptor antagonists — SUSTOL
`(Granisetron injection — extended release), neurokinin1-receptor
`antagonists — Varubi / Varuby (rolapitant)], and geography.
`
`e Nausea and vomiting are serious side effects of cancer
`chemotherapy that can cause significant negative impacts on
`patients’ quality of life and on their ability to tolerate and
`comply with therapy.
`
`e Despite advances in the prevention and management of
`chemotherapy-induced nausea and vomiting (CINV), these
`side effects remain among the most distressing for patients.
`
`e The use of emerging antiemetic medications has
`reduced the incidence of vomiting substantially, but
`evaluations show that approximately 30% to 60% of
`patients still experience either acute or delayed nausea
`after chemotherapy.
`
`e Based on the marketed products category, the Aloxi
`(palonosetron) drug segment accounted for the largest share
`of the total CINV market.
`
`e Currently, four 5-HT3 receptor antagonists are available in
`the United States -ondansetron, granisetron, dolasetron,
`and palonosetron.
`
`e Since their introduction, 5-HT3 receptor antagonists
`have become part of the cornerstone for CINV
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 4/12
`
`Page 4 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`effect profile.
`
`e Aloxi is one of the most commonly prescribed drugs to
`treat CINV. Palonosetron, the newest agent, was approved
`in 2003.
`
`e |tisis available in oral as well as IV dosage forms,
`indicated in adults for the prevention of acute and
`delayed nausea and vomiting associated with moderate
`to high emetogenic chemotherapy.
`
`e Evidence suggests that the 5-HT3-receptor
`antagonists administered in combination with
`corticosteroids afford the best protection from
`symptoms of acute emesis and, by extrapolation, the
`most effective prevention of delayed emesis.
`
`The global CINV treatment market research report is further divided
`by geography North America (U.S., Canada), Europe (U.K., Germany,
`France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest
`of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the
`World.
`
`e Geographically, the North America region represented the
`largest market share of the total CINV drugs in terms of
`revenue, followed by the Europe region, primarily due to the
`increasing incidence of various types of cancer and anticipated
`product approval during the next few years.
`
`e On the other hand, the emerging markets in the Asia Pacific
`region expected to exhibit huge opportunities characterized
`by increasing market penetration by generic manufacturers,
`durina the forecast period.
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 5/12
`
`Page 5 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`(market drivers, restraints, opportunities), market attractiveness
`analysis and profiles of major competitors in the global market
`including company overview, financial snapshot, key products,
`technologies and services offered, and recent developments.
`
`Major competitors operating in the global market for chemotherapy-
`induced nausea and vomiting treatment and included in this report
`are GSK plc (Tesaro, Inc. / GlaxoSmithKline), Helsinn Holding S.A.,
`Heron Therapeutics, Inc., Merck & Co., Inc., and Ono Pharmaceutical
`Co., Ltd.
`
`e Product
`e Marketed Drugs
`e 5-HT3-receptor Antagonists (5-HT3RAs)
`e Aloxi (palonosetron)
`* Anzemet (dolasetron)
`e Zofran Generic (ondansetron)
`e Kytril Generic (granisetron)
`e Neurokinin1-receptor Antagonists (NK1RAs)
`e Emend (aprepitant) / Proemend (fosaprepitant
`meglumine) / Cinvanti (aprepitant)
`e Netupitant-Palonosetron Fixed-Dose Combination IV
`(NEPA FDCQ)
`e Akynzeo (netupitant/palonosetron FDC)
`e Pipeline Drugs
`e 5-HT3-receptor Antagonists (5-HT3RAs)
`e SUSTOL (Granisetron Injection — extended release)
`e Neurokinin1-receptor Antagonists (NK1RAs)
`e Varubi / Varubv (rolanitant)
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 6/12
`
`Page 6 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`Limited-Time Offer [Flat 15% Discount] Dismiss
`e North America (U.S., Canada)
`
`e Europe (U.K, Germany, France, Italy, Spain, Rest of EU)
`e Asia Pacific (Japan, China, India, Rest of APAC)
`e Latin America (Brazil, Mexico, Rest of LA)
`e Rest of the World
`e Company Profiles
`e GSK plc (Tesaro, Inc. / GlaxoSmithKline)
`e Helsinn Holding S.A. (Helsinn Healthcare/ Helsinn Group)
`e Heron Therapeutics, Inc.
`e Merck & Co., Inc.
`e Ono Pharmaceutical Co., Ltd.
`
`To request Table of Contents and Sample Pages of this report visit:
`https:.//www.ihealthcareanalyst.com/report/chemotherapy-induced-
`nausea-and-vomiting-drugs-market/
`
`Related publications:
`
`e Chemotherapy-Induced Nausea and Vomiting Drugs Market by
`Major Drugs (Marketed Drugs, and Pipeline Drugs) and
`Forecast 2024-2031
`
`e Post-operative Nausea and Vomiting (PONV) Market by
`Treatment (Pharmacological Treatment — Dopamine
`Antagonists, NK-1 Receptor Antagonists, Serotonin
`Antagonists, Steroids, and Non-pharmacological Treatment); by
`Distribution Channel (Hospital Pharmacies, Online Pharmacies,
`Retail Pharmacies & Drug Stores) and Forecast 2024-2031
`
`e Global mHealth Services Market $315 Billion by 2031
`
`e Global Anticoaaulant Druas Market $32.7 Billion bv 2029
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/
`
`Page 7 of 12
`
`7112
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`2029
`
`BB Press Releases
`< Global Video Telemedicine Market $3.4 Billion by 2031
`
`> Global Airway Clearance Devices Market $870 Million by 2031
`Request Table of Contents/Sample Analysis
`
`Full Name*
`
`Company Email*
`
`Phone Number* [Please add country code]
`
`Subject*
`
`Global Chemotherapy-inc
`
`Message*
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 8/12
`
`Page 8 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`Market Data Matrix
`
`Market Value | Market Volume | Epidemiology | Clinical Trials | Patent
`Landscape | Regulatory Approvals | COVID-19 Impact Analysis
`
`Recent Publications
`
`Global Ambulatory Surgical and Emergency Center Services Market $125
`Billion by 2031
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 9/12
`
`Page 9 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`Limited-Time Offer [Flat 15% Discount] Dismiss
`
`Global Emphysema Treatment Devices Market $2.9 Billion by 2031
`
`Global Chronic Low Back Pain Devices Market $17.5 Billion by 2031
`
`Global Metabolic Bone Diseases Devices Market $7.5 Billion by 2031
`
`Global Tumor Microwave Ablation Market $282 Million by 2031
`
`Global Epilepsy Treatment Devices Market $7.4 Billion by 2031
`
`Global Surgical Robots Market $135 Billion by 2031
`
`Global Uterine Fibroids Embolization Devices Market $3.5 Billion by 2031
`
`Global Contrast Media Formulations Market $11.2 Billion by 2031
`
`Global Multi-Cancer Early Detection Assays Market $3.5 Billion by 2031
`
`Global Minimal Residual Disease Diagnostics Market $5.1 Billion by 2031
`
`Global Atrial Fibrillation Therapy Devices Market $19.5 Billion by 2031
`
`Global Bone Cancer Regeneration and Repair Devices Market $3.5 Billion
`by 2031
`
`Revenue Forecasting Techniques for New Pharmaceutical Drugs
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 10/12
`
`Page 10 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`Receive latest published reports, industry trends and future market outlook.
`
`Full Name*
`
`Company Email*
`
`Phone Number* [Please add country code]
`
`Resource Links
`
`e About Us
`
`e Clinical Trials
`
`e Drugs@FDA
`
`e Orange Book
`
`e Premarket Approval
`
`e Premarket Notification
`e Publications
`
`Terms and Conditions
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 1112
`
`Page 11 of 12
`
`
`
`
`
`
`
`
`7/31/25, 12:28 PM Global CINV Drugs Market $4.3 Billion by 2031
`
`e (Careers
`
`e Terms of Use
`
`e How to Order
`
`e Return Policy
`
`e Privacy Policy
`
`e Disclaimer Policy
`
`Secure Online Payment
`
`[ 2 eem——.] | |
`VISA mflg = PayPal
`
`Search
`
`Contact Address
`
`US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043,
`United States
`
`Phone: +1 (314) 315-4764
`
`India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager,
`Pune 411005, India
`
`Phone: +91 (20) 25898524
`
`Email: sales@ihealthcareanalyst.com
`
`https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/ 12/12
`
`Page 12 of 12
`
`
`
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
